Glutamine protects against doxorubicin-induced cardiotoxicity

Journal of Surgical Research

Volumn 85, Issue 1, 1999, Pages 178-182

  Cao, Yihong ^a   Kennedy, Richard ^a   Klimberg, V Suzanne ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Doxorubicin; Glutamine; Glutathione

Indexed keywords

DOXORUBICIN; FREAMINE; GLUTAMINE; GLUTATHIONE; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DIET SUPPLEMENTATION; FEMALE; HEART PROTECTION; INTRAVENOUS DRUG ADMINISTRATION; LIPID PEROXIDATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

EID: 0032789085     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1006/jsre.1999.5677     Document Type: Article

References (40)

1. Curran C. F., Narang P. K., Reynolds R. D. Toxicity profile of dexrazoxane (Zinecard®, ICRF-187, ADR-529, NSC-169780), a modulator of doxorubicin cardiotoxicity. Cancer Treat. Rev. 18:1991;241.
2. Gaudin P. B., Hruban R. H., Beschorner W. E., Kasper E. K., Olson J. L., Baughman K. L., Hutchins G. M. Myocarditis associated with doxorubicin cardiotoxicity. Am. J. Clin. Pathol. 100:1993;158.
3. VonHoff D. D., Layard M. W., Basa P., Davis H. L. Jr., VonHoff A. L., Rozenscweig M., Muggia F. M. Risk factors for doxorubicin induced congestive heart failure. Ann. Intern. Med. 91:1979;710.
4. Gottdiener J. S., Appelbaum F. R., Ferrans V. J., Deisseroth A., Ziegler J. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch. Intern. Med. 141:1981;758.
5. Porembka D. T., Lowder J. N., Orlowski J. P., Bastulli J., Lockrem J. Etiology and management of doxorubicin cardiotoxicity. Crit. Care Med. 17:1989;569.
6. Handa K., Sato S. Generation of free radicals of quinone group containing anti-cancer chemicals in NADPH-microsome system as evidenced by initiation of sulfate oxidations. Gann. 66:1975;43.
7. Handa K., Sato S. Stimulation of microsomal NADPH reduction by quinone group containing anticancer chemicals. Gann. 67:1975;523.
8. Sato S., Iwazumi M., Handa K. Electron spin resonance study on the mode of generation of free radicals by daunorubicin, adriamycin and carboquine in NADPH microsomal system. Gann. 68:1977;803.
9. Boucek R. J. Jr., Kunkel E. M., Graham T. P. Jr., Brenner D. E., Olson R. D. Doxorubicinol, the metabolite of doxorubicin, is more cardiotoxic than doxorubicin. Pediatr. Res. 21:1987;187A.
10. Rouse K., Nwokedi E., Woodliff J., Epstein J., Klimberg V. S. Glutamine enhances sensitivity of chemotherapy through changes in glutathione metabolism. Ann. Surg. 221:1995;420.
11. Vanderpool, D, and, Klimberg, V. S. Oral glutamine protects against cyclophosphamide induced cardiotoxicity and death through changes in glutathione metabolism. Abstracts of the Association of Academic Surgeons, Nov. 11, 1993, Hershey, PA.
12. Kennedy R. H., Wyeth R. P., Seifen E. Effects of doxorubicin on cardiac motility, glutathione and lipid peroxidation. FASEB J. 10:1996;A169.
13. Bergmeyer, H. U. Methods of Enzymatic Analysis, New York, Wiley, 1974. P, 1704.
14. Tietze F. Enzymatic method for quantitative determination of nanogram amounts of total and oxidized glutathione: Applications to mammalian blood and other tissues. Ann. Biochem. 27:1969;502.
15. Anderson M. E. Enzymatic and chemical methods for the determination of glutathione. Dolphin D. Glutathione. 1983;340-365 Wiley, New York.
16. Griffith O. W. Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal. Biochem. 106:1980;207.
17. Ohkawa H., Ohishi N., Yage K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95:1979;351.
18. McFalls E. O., Paulson D. J., Gilbert E. F., Shug A. L. Carnitine protection against adriamycin-induced cardiomyopathy in rats. Life Sci. 38:1986;497.
19. Strohm G. H., Payne C. M., Alberts D. S. Cardiotoxic effects of doxorubicin with and without carnitine. Arch. Pathol. Lab. Med. 106:1982;181.
20. Hamaguchi T., Azuma J., Atwata N. Reduction of doxorubicin-induced cardiotoxicity in mice by taurine. Res. Commun. Chem. Pathol. Pharmacol. 59:1988;21.
21. Shimpo K., Nagatsu T., Yamada K. Ascorbic acid and adriamycin toxicity. Am. J. Clin. Nutr. 54:1991;1298S.
22. Myers C. E., Bonow R., Palmeri J. A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin. Oncol. 10:1983;53.
23. Sonneveld P. Effect of alpha tocopherol on the cardiotoxicity of adriamycin in the rat. Cancer Treat. Rep. 62:1978;1033.
24. Wang Y. M., Madanat F. F., Kimball J. C. Effect of vitamin E against adriamycin-induced toxicity in rabbits. Cancer Res. 49:1968;1022.
25. Legha S., Wang Y. M., Mackay B. Clinical and pharmacologic investigation of the effects of alpha tocopherol on adriamycin cardiotoxicity. Annu. Rev. Biochem. 55:1986;1151.
26. Doroshow J. H., Locker G. Y., Ifrim I., Myers C. E. Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine. J. Clin. Invest. 68:1981;1053.
27. Herman E. H., Ferrans V. J. Amelioration of chronic antracycline cardiotoxicity by ICRF-187 and other compounds. Cancer Treat. Rev. 14:1987;225.
28. Unverferth D. V., Leier C. V., Balcerzak S. P., Hamlin R. Usefulness of a free radical scavenger in preventing doxorubicin-induced heart failure in dogs. Am. J. Cardiol. 56:1985;157.
29. Danesi R., Bernardini N., Marchetti. Protective effects of fructose-1,16-diphosphate on acute and chronic doxorubicin cardiotoxicity in rats. Cancer Chemother. Pharmacol. 25:1990;326.
30. Herman E. H., Mahtre R. M., Chadwick D. P. Modification of some of the toxic effects of daunomycin (NSC-82151) by pretreatment with the antineoplastic agent ICRF-159 (NSC-129, 943). Toxicol. Appl. Pharmacol. 27:1974;517.
31. Hu S. T., Brandle E., Zbinden G. Inhibition of cardiotoxic, nephrotoxic and neurotoxic effects of doxorubicin by ICRF-159. Pharmacology. 26:1983;210.
32. Yeung T. K., Jaenke R. S., Wilding D., Creighton A. M., Hopewell J. W. The protective activity of ICRF-187 against doxorubicin-induced cardiotoxicity in the rat. Cancer Chemother. Pharmacol. 30:1992;58.
33. Speyer J. L., Green M. D., Kramer E. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N. Engl. J. Med. 3191:1988;745.
34. Olson R. D., Boerth R. C., Gerber J. G., Nies A. S. Mechanism of adriamycin cardiotoxicity: Evidence for oxidative stress. Life Sci. 29:1981;1393.
35. Julicheret R. H. M., Sterrenberg L., Bast A., Riksen R. O. W. M., Koomen J. M., Noordhoek J. The role of lipid peroxidation in acute doxorubicin-induced cardiotoxicity as studied in rat isolated heart. J. Pharm. Pharmacol. 38:1986;277.
36. Julka D., Sandhir R., Gill K. D. Adriamycin-induced oxidative stress in rat central nervous system. Biochem. Mol. Biol. Int. 29:1993;807.
37. Alderton P., Gross J., Green M. D. Role of (±)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane cardiomyopathy. Cancer Res. 50:1990;5136.
38. Villani F., Galimberti M., Zunino F., Monti E., Rozza A., Lanza E., Favalli L., Poggi P. Prevention of doxorubicin-induced cardiomyopathy by reduced glutathione. Cancer Chemother. Pharmacol. 28:1991;365.
39. Welbourne T. C. Ammonia production and glutamine incorporation into glutathione in the fractioning rat kidney. Cancer J. Biochem. 59:1979;629.
40. Rouse K., Nwokedi E., Woodliff J., Epstein J., Klimberg V. S. Glutamine enhances sensitivity of chemotherapy through changes in glutathione metabolism. Ann. Surg. 221:1995;420.